Kyowa Kirin Co., Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KYKOF research report →
About the company
Kyowa Kirin Co. , Ltd. is a global pharmaceutical company engaged in the development, manufacturing, and commercialization of medicines, with a primary focus on therapeutic areas including oncology, nephrology, central nervous system disorders, and immunological conditions.
- CEO
- Abdul Hafeez Mullick
- IPO
- 2012
- Employees
- 5,669
- HQ
- Tokyo, JP
Price Chart
- Market Cap
- $7.55B
- P/E
- 19.12
- P/S
- 2.73
- P/B
- 1.56
- EV/EBITDA
- 9.20
- Div Yield
- 2.52%
- Gross Margin
- 73.30%
- Op Margin
- 21.54%
- Net Margin
- 14.28%
- ROE
- 8.39%
- ROIC
- 9.32%
- Revenue
- $497.26B · 0.34%
- Net Income
- $67.10B · 12.07%
- EPS
- $128.18 · 13.37%
- Op Income
- $102.36B
- FCF YoY
- 257.70%
- 52W High
- $18.00
- 52W Low
- $12.42
- 50D MA
- $14.60
- 200D MA
- $15.21
- Beta
- 0.11
- Avg Volume
- 583
Get TickerSpark's AI analysis on KYKOF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our KYKOF coverage
Recent articles, reports, and earnings notes.
No research on KYKOF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KYKOF report →Similar companies
Peers in the same neighborhood.